Article
Clinical Neurology
Michelle Cohen, Madeline Nguyen, Chad D. Nix, Brendan Case, Joshua P. Nickerson, Jacqueline Bernard, Julia Durrant, Delaram Safarpour, Tarvez Tucker, Kamila Vagnerova, William B. Messer
Summary: This article presents a rare case of a patient who developed YEL-AND following vaccination, and imaging findings consistent with variant Creutzfeldt Jakob Disease were discovered. This is a rare report on the intracranial imaging progression of this disease.
FRONTIERS IN NEUROLOGY
(2022)
Article
Immunology
Flora de Andrade Gandolfi, Cassia Fernanda Estofolete, Marcia Catelan Wakai, Andreia Francesli Negri, Michela Dias Barcelos, Nikos Vasilakis, Mauricio Lacerda Nogueira
Summary: The disease burden of yellow fever virus infection is high in areas with low vaccination coverage. Vaccination is the most effective control strategy for yellow fever, with the licensed vaccines being safe and effective. However, rare cases of neurotropic disease have been observed following vaccination. This report emphasizes the importance of healthcare professionals being aware of and managing such events promptly.
Article
Public, Environmental & Occupational Health
Andrey Rojas, Wayne Hachey, Gurpreet Kaur, Joanna Korejwo, Riyadh Muhammad
Summary: Due to a shortage of the yellow fever vaccine YF-VAX, the alternative vaccine STAMARIL was imported into the USA. The enhanced safety surveillance showed that STAMARIL had a good safety profile, with very rare serious adverse events that were consistent with known safety information.
JOURNAL OF TRAVEL MEDICINE
(2023)
Article
Immunology
Shaleesa Ledlie, Christina Ricci, Chunshen Pan, Andrey Rojas, Alena Khromava, Lin Li
Summary: This study provides updated insights into the current usage of yellow fever (YF) vaccines among civilian recipients in the US and supports the safety profile of these vaccines in US practice. The low prevalence of pre-existing immunosuppressive medical conditions among vaccine recipients indicates good adherence to vaccination guidelines by healthcare practitioners. The risk of developing neurotropic and viscerotropic diseases post-vaccination remains rare.
Review
Biotechnology & Applied Microbiology
Gerardo Montalvo Zurbia-Flores, Christine S. Rollier, Arturo Reyes-Sandoval
Summary: Despite the effectiveness of the yellow fever vaccine, issues such as contraindications and inadequate supply have led to the search for novel vaccine candidates to better control the disease.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Review
Medicine, Research & Experimental
Jose Tuells, Andres F. Henao-Martinez, Carlos Franco-Paredes
Summary: Despite the availability of a vaccine, yellow fever remains a significant preventable disease in endemic regions. Yellow fever is a viral hemorrhagic fever that has had a major impact on human societies. Throughout history, it has caused epidemics and played a role in shaping modern societies. Efforts of scientists have led to the discovery of the virus and the development of a vaccine. In the present day, it is important to enhance immunization activities, ensure fair distribution of vaccines, immunize at-risk populations during outbreaks, and promote vaccination among international travelers.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Review
Immunology
Jolynne Mokaya, Derick Kimathi, Teresa Lambe, George M. Warimwe
Summary: Yellow fever remains a global health threat, with efforts to eliminate it by vaccinating one billion people at risk by 2026. The current vaccine provides good protection, but production challenges limit its use, leading to exploration of alternative dosing strategies. Understanding immune responses to vaccination and exploring antibody characteristics and cell-mediated immunity are important for developing a comprehensive understanding of protective immunity.
Article
Immunology
J. Xiang, Q. Chang, J. H. McLinden, N. Bhattarai, J. L. Welch, T. M. Kaufman, Jack T. Stapleton
Summary: Live attenuated vaccines such as the yellow fever virus vaccine can modulate immune functions, but they may also have off-target effects on T-cell receptor signaling, which could impact clinical outcomes.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Virology
Tamiris Azamor, Andrea Marques Vieira da Silva, Juliana Gil Melgaco, Ana Paula dos Santos, Caroline Xavier-Carvalho, Lucia Elena Alvarado-Arnez, Leonardo Ribeiro Batista-Silva, Denise Cristina de Souza Matos, Camilla Bayma, Sotiris Missailidis, Ana Paula Dinis Ano Bom, Milton Ozorio Moraes, Patricia Cristina da Costa Neves
Summary: The yellow fever vaccine YF17DD induces potent immune responses, with CLEC5A(+) monocyte activation occurring five days after vaccination and early positive correlations between CD4(+) and CD8(+)T cell activation and type II interferon. Certain genotypes, such as rs2430561, rs2069718, and rs13237944, are associated with higher expression levels of IFNG and CLEC5A, potentially playing a key role in the long-lasting immunity elicited by YF17DD.
Article
Biochemistry & Molecular Biology
Stephane Fraga de Oliveira Tosta, Mariana Santana Passos, Rodrigo Kato, Alvaro Salgado, Joilson Xavier, Arun Kumar Jaiswal, Siomar C. Soares, Vasco Azevedo, Marta Giovanetti, Sandeep Tiwari, Luiz Carlos Junior Alcantara
Summary: Yellow fever is a re-emerging major health issue causing recent outbreaks with high mortality rates, mainly affecting tropical countries in Africa and South America. The development of a multi-epitope vaccine for Yellow fever virus using immunoinformatics approaches shows potential in stimulating both humoral and cellular immune responses, making it a candidate for further experimental validation.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2021)
Review
Public, Environmental & Occupational Health
Roshina Gnanadurai, Ines Campos-Matos, Sanch Kanagarajah, Katie Geary, Hilary Simons, Dipti Patel
Summary: This study evaluated the number and type of yellow fever (YF) vaccine incidents in England, Wales and Northern Ireland (EWNI) and found that most incidents were due to incorrect timing or other errors. However, vaccination in contraindicated individuals resulted in one death. These findings helped improve the work and staff training in vaccination centers.
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2022)
Article
Ophthalmology
Roberto Vignapiano, Lidia Vicchio, Eleonora Favuzza, Michela Cennamo, Rita Mencucci
Summary: This case report describes a 48-year-old man who developed corneal graft rejection in the left eye after a yellow fever vaccination, with full recovery after a short course of systemic and topical steroid treatment. It highlights the importance of being aware of vaccine-related complications, especially those that may potentially threaten vision.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Pediatrics
Cal Robinson, Rahul Chanchlani, Anastasia Gayowsky, Sandeep Brar, Elizabeth Darling, Catherine Demers, Jennifer Klowak, Braden Knight, Ellen Kuenzig, Tapas Mondal, Rulan Parekh, Hsien Seow, Carolina Jimenez-Rivera, Richard Webster, Stephen Fung, Eric I. Benchimol, Michelle Batthish
Summary: The incidence of KD is increasing in Ontario, leading to greater healthcare utilization, with older children more likely to experience complications.
PEDIATRIC RESEARCH
(2021)
Article
Medicine, General & Internal
Ji Ma, Michael Bright Yakass, Sander Jansen, Bert Malengier-Devlies, Dominique Van Looveren, Lorena Sanchez-Felipe, Thomas Vercruysse, Birgit Weynand, Mahadesh Prasad Arkalagud Javarappa, Osbourne Quaye, Patrick Matthys, Tania Roskams, Johan Neyts, Hendrik Jan Thibaut, Kai Dallmeier
Summary: This study demonstrates that the YF-S0 vaccine can induce strong humoral and cellular immunity against yellow fever virus (YFV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters, providing full protection against YFV infection and SARS-CoV-2 strain B1.1.7 (Alpha variant) infection. Importantly, strong pre-existing immunity against the YF17D vector does not interfere with the efficacy of YF-S0 vaccination.
Review
Chemistry, Medicinal
Clairissa A. Hansen, Alan D. T. Barrett
Summary: Yellow fever is a disease prevented by the 17D vaccine, but remains a major public health burden due to supply and demand issues. The World Health Organization has initiated the Eliminate Yellow Fever Epidemics (EYE) initiative, and second-generation vaccine candidates must demonstrate their safety and immunogenicity.